Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Hsp90 inhibition by AUY92… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma

Artikel i vetenskaplig tidskrift
Författare S. Steinmann
H. Gali-Muhtasib
K. Huebner
R. Al-Halabi
R. Abou Merhi
Pierre Åman
A. Agaimy
F. Haller
R. Schneider-Stock
Publicerad i Cancer Letters
Volym 367
Nummer/häfte 2
Sidor 147-156
ISSN 0304-3835
Publiceringsår 2015
Publicerad vid Institutionen för biomedicin, avdelningen för patologi
Sahlgrenska Cancer Center
Sidor 147-156
Språk en
Länkar dx.doi.org/10.1016/j.canlet.2015.07...
Ämnesord Liposarcoma, Hsp90-inhibition, NVP-AUY922, Myxoid, GASTROINTESTINAL STROMAL TUMOR, CANCER CELLS, PATHWAY, APOPTOSIS, KINASE, GROWTH, EXTREMITY, SURVIVAL, IMATINIB, Oncology
Ämneskategorier Cancer och onkologi

Sammanfattning

Liposarcoma is one of the most common soft tissue sarcomas in adults. Recognized histological subtypes include well differentiated/dedifferentiated liposarcoma (WD/DDLS), myxoid liposarcoma (MLS) and pleomorphic liposarcoma. Currently, there are no proper subtype-specific treatments due to the genetic, histological and clinical heterogeneity of the liposarcoma subentities. In the past decade, the rising understanding of the various genetic and molecular aberrations in liposarcoma led to the development of novel alternative therapeutic strategies. One such therapy is the inhibition of the heat shock protein 90 (Hsp90) which is overexpressed in liposarcomas. In this study, we dissect the functional role of a novel potent Hsp90 inhibitor NVP-AUY922 (AUY922) in different cell lines of myxoid (ML5402, MLS1765) and undifferentiated (SW872) liposarcomas. We show that compared with 17-AAG treatment, lower concentrations of AUY922 achieve markedly cytotoxic effects on tumor cell viability. Combination treatment of AUY922 (20 nM) with Doxorubicin (300 nM) yielded a further reduction in cell viability in comparison to Doxorubicin alone. In vivo, we document an inhibition of tumor growth after AUY922 treatment. Further analyses revealed that Hsp90-inhibition induces apoptotic cell death and cell cycle arrest. In addition, we report striking perturbations of subtype-specific pattern in Raf/MEK/ERK and PI3K signaling after AUY922 application. In conclusion, our results provide evidence that Hsp90-inhibition by AUY922 may be a promising alternative therapeutic strategy for myxoid liposarcoma patients. (C) 2015 Published by Elsevier Ireland Ltd.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?